Analyst Activity – Maxim Group Reiterates Hold on Celsion (NASDAQ:CLSN)

15

Analyst Ratings For Celsion (NASDAQ:CLSN)

Today, Maxim Group reiterated its Hold rating on Celsion (NASDAQ:CLSN).

There are 1 hold rating, 2 buy ratings on the stock.

The current consensus rating on Celsion (NASDAQ:CLSN) is Buy (Score: 2.67) with a consensus target price of $2.33 per share, a potential 693.65% upside.

Some recent analyst ratings include

  • 4/20/2017-Maxim Group Reiterated Rating of Hold.
  • 4/10/2017-Rodman & Renshaw Reiterated Rating of Buy.
  • 4/10/2017-HC Wainwright Reiterated Rating of Buy.
  • 11/24/2015-Cantor Fitzgerald Reiterated Rating of Not Available .
  • 7/13/2015-BTIG Research initiated coverage with a Buy rating.

Dividend information for Celsion (NASDAQ:CLSN)

.
Recent Insider Trading Activity For Celsion (NASDAQ:CLSN)
Celsion (NASDAQ:CLSN) has insider ownership of 7.96% and institutional ownership of 10.74%.

  • On 2/21/2017 Alberto R Martinez Jr, Director, bought 35,000 with an average share price of $0.23 per share and the total transaction amounting to $8,050.00. View SEC Filing
  • On 2/15/2017 Alberto R Martinez Jr, Director, bought 45,000 with an average share price of $0.22 per share and the total transaction amounting to $9,900.00. View SEC Filing
  • On 11/14/2016 Alberto R Martinez Jr, Director, bought 10,000 with an average share price of $0.86 per share and the total transaction amounting to $8,600.00. View SEC Filing
  • On 11/11/2016 Alberto R Martinez Jr, Director, bought 10,000 with an average share price of $0.91 per share and the total transaction amounting to $9,100.00. View SEC Filing
  • On 10/7/2016 Michael H Tardugno, Chairman, bought 10,000 with an average share price of $1.14 per share and the total transaction amounting to $11,400.00. View SEC Filing
  • On 8/16/2016 Alberto R Martinez Jr, Director, bought 5,000 with an average share price of $1.25 per share and the total transaction amounting to $6,250.00. View SEC Filing
  • On 6/17/2016 Alberto R Martinez Jr, Director, bought 5,000 with an average share price of $1.35 per share and the total transaction amounting to $6,750.00. View SEC Filing

About Celsion (NASDAQ:CLSN)
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Recent Trading Activity for Celsion (NASDAQ:CLSN)
Shares of Celsion closed the previous trading session at 0.294 up +0.018 6.41% with 963,159 shares trading hands.

An ad to help with our costs